Ketamine, a glutamate N-methyl-d-aspartate (NMDA) receptor antagonist, has shown rapid antidepressant effects, but small study groups and inadequate control conditions in prior studies have precluded a definitive conclusion.
This study suggests that ketamine is effective in treatment-resistant bipolar depression and may reduce suicidal ideation and anhedonia.
At least 10-20% of the patients suffering from depression meet criteria for treatment-resistant depression (TRD)...
Our meta-analysis suggests that single administrations ketamine therapy are efficacious in the rapid treatment of unipolar and bipolar depression.
Several studies now provide evidence of ketamine hydrochloride's ability to produce rapid and robust antidepressant effects in patients with mood and anxiety disorders that were previously resistant to treatment.
The clinical use of ketamine infusion therapy for psychiatric disorders and chronic pain management continues to evolve.
Beneficial effects of ketamine in a chronic pain state with allodynia, possibly due to central sensitization
Allodynia is a well-known component of neuropathic pain resulting from injury to the nervous system.
Prolonged Analgesic Effect of Ketamine, anN-Methyl-d-Aspartate Receptor Inhibitor, in Patients with Chronic Pain
We examined the role of N-methyl-D-aspartate (NMDA) receptors in chronic (pathological) pain in humans by using the NMDA receptor antagonist ketamine as a probe.